Trial Profile
An Open-Label, Dose Escalation, Phase I Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Nonhematologic Malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Pevonedistat (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Takeda Oncology
- 29 Jul 2019 A population pharmacokinetic analysis was conducted to quantify the impact of patient-specific and concurrent medication factors on pevonedistat pharmacokinetics using pooled data from 6 clinical studies ; results published in the British Journal of Clinical Pharmacology
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.